Alzheimer's Disease Trial, Recruiting NCT06372587 Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT06372587
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who show clear clinical signs that meet the criteria for a probable diagnosis of Alzheimer's disease
  • People between the ages of 18 and 80 years old
  • People who have signed a form agreeing to take part in the trial

Who may not be able to join:

  • People who have other neurological (brain or nervous system) diseases
  • People who have blood clotting disorders or who are currently taking blood-thinning medications
  • People who have skin conditions or connective tissue diseases (conditions affecting tissues that support and connect the body)
  • People who have other physical or mental health conditions, or abnormal test results, that could interfere with their ability to participate or affect the reliability of the study results
  • People who are unable to give their own informed consent to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
19 December 2023
Est. completion
30 December 2024

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

To use genetically encoded engineered proteins to obtain an inducible control of their activity in living human neurons preventing dendritic spines loss; To leverage genetically encoded engineered proteins to prevent alterations in the morphology of dendritic spines in living human neurons; To use genetically encoded engineered proteins to obtain an inducible control of their activity in living human neurons promoting functional synaptic plasticity; To use genetically encoded engineered proteins to obtain evaluate neuronal excitability in living human neurons

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov